Gentel to Collaborate with SCOPE Consortium | GenomeWeb

NEW YORK (GenomeWeb News) – Gentel Biosciences will collaborate with an international consortium focused on developing biomarkers for pregnancy complications, the company said.

The Screening for Pregnancy Endpoints (SCOPE) Study is establishing a pregnancy biobank that will be used to research tests that can predict major diseases of late-stage pregnancy, which affect 19 percent of worldwide pregnancies, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.